JP2008501802A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501802A5
JP2008501802A5 JP2007527639A JP2007527639A JP2008501802A5 JP 2008501802 A5 JP2008501802 A5 JP 2008501802A5 JP 2007527639 A JP2007527639 A JP 2007527639A JP 2007527639 A JP2007527639 A JP 2007527639A JP 2008501802 A5 JP2008501802 A5 JP 2008501802A5
Authority
JP
Japan
Prior art keywords
solid dispersion
pharmaceutical composition
polymer
amorphous
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007527639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501802A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/019929 external-priority patent/WO2005123076A2/en
Publication of JP2008501802A publication Critical patent/JP2008501802A/ja
Publication of JP2008501802A5 publication Critical patent/JP2008501802A5/ja
Pending legal-status Critical Current

Links

Images

JP2007527639A 2004-06-08 2005-06-08 医薬組成物 Pending JP2008501802A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57804304P 2004-06-08 2004-06-08
PCT/US2005/019929 WO2005123076A2 (en) 2004-06-08 2005-06-08 Pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012000814A Division JP5337262B2 (ja) 2004-06-08 2012-01-05 医薬組成物

Publications (2)

Publication Number Publication Date
JP2008501802A JP2008501802A (ja) 2008-01-24
JP2008501802A5 true JP2008501802A5 (https=) 2008-07-24

Family

ID=35510250

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007527639A Pending JP2008501802A (ja) 2004-06-08 2005-06-08 医薬組成物
JP2012000814A Expired - Fee Related JP5337262B2 (ja) 2004-06-08 2012-01-05 医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012000814A Expired - Fee Related JP5337262B2 (ja) 2004-06-08 2012-01-05 医薬組成物

Country Status (18)

Country Link
US (2) US20060089385A1 (https=)
EP (1) EP1765283A4 (https=)
JP (2) JP2008501802A (https=)
KR (2) KR20120039763A (https=)
CN (2) CN1988885A (https=)
AR (1) AR049297A1 (https=)
AU (1) AU2005253957B2 (https=)
BR (1) BRPI0511900A (https=)
CA (1) CA2569310A1 (https=)
IL (2) IL179809A (https=)
MX (1) MXPA06014253A (https=)
NO (1) NO20070130L (https=)
NZ (1) NZ588471A (https=)
RU (1) RU2373923C2 (https=)
SG (1) SG153800A1 (https=)
TW (1) TWI389688B (https=)
WO (1) WO2005123076A2 (https=)
ZA (2) ZA200700030B (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1019A (en) * 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
UY28500A1 (es) * 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
TWI437990B (zh) * 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
NZ563365A (en) 2005-06-02 2011-02-25 Schering Corp Combination of HCV protease inhibitors with a surfactant
NZ563361A (en) 2005-06-02 2011-02-25 Schering Corp HCV protease inhibitors in combination with food
AU2006275413B2 (en) * 2005-08-02 2012-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AU2007217355B2 (en) * 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
CA2645684A1 (en) * 2006-03-06 2007-09-13 Abbott Laboratories Compositions and methods of use of ritonavir for treating hcv
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
US20070218138A1 (en) * 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
TWI428125B (zh) * 2006-03-20 2014-03-01 Vertex Pharma 對包括vx-950之藥物實施噴霧乾燥之方法及由此方法製備之產物
WO2007120595A2 (en) * 2006-04-11 2007-10-25 Novartis Ag Amines for the treatment of hcv
AU2007249668B2 (en) 2006-04-11 2011-04-07 Novartis Ag HCV/HIV inhibitors and their uses
MX2009006806A (es) * 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
WO2008074035A1 (en) * 2006-12-27 2008-06-19 Abbott Laboratories Hcv protease inhibitors and uses thereof
CN101668527A (zh) * 2007-02-23 2010-03-10 阿韦拉制药股份有限公司 药物制剂
HRP20120330T1 (hr) * 2007-02-27 2012-05-31 Vertex Pharmaceuticals Incorporated Sukristali i farmaceutski pripravci koji ih sadrže
WO2008106058A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CL2008000746A1 (es) * 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
EP2000139A1 (en) * 2007-06-07 2008-12-10 Novartis AG Stabilized amorphous forms of imatinib mesylate
NZ583699A (en) * 2007-08-30 2012-04-27 Vertex Pharma Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
JP5161528B2 (ja) * 2007-10-02 2013-03-13 浜松ホトニクス株式会社 パクリタキセル微粒子、パクリタキセル微粒子分散液、および、これらの製造方法
JP5149585B2 (ja) * 2007-10-02 2013-02-20 浜松ホトニクス株式会社 微粒子分散液製造方法
CN101868452B (zh) 2007-10-10 2014-08-06 诺华股份有限公司 螺环吡咯烷类与其对抗hcv和hiv感染的应用
AU2008313620A1 (en) * 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product containing N-aryl urea-based compound
WO2009061395A2 (en) * 2007-11-05 2009-05-14 Vertex Pharmaceuticals Incorporated Hcv combination therapies
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EA201170484A1 (ru) 2008-09-24 2012-03-30 Вертекс Фармасьютикалз Инкорпорейтед Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
WO2010093843A2 (en) 2009-02-12 2010-08-19 Vertex Pharmaceuticals Incorporated Hcv combination therapies
KR101739994B1 (ko) 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
WO2011103933A1 (en) * 2010-02-25 2011-09-01 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg PROCESS FOR THE PREPARATION OF α-ACYLOXY β-FORMAMIDO AMIDES
EP2593105A1 (en) 2010-07-14 2013-05-22 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition comprising vx-950
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
EP2654726A1 (en) * 2011-03-08 2013-10-30 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
HK1201186A1 (en) * 2011-12-29 2015-08-28 Abbvie Inc. Solid compositions comprising an hcv inhibitor
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US20130195797A1 (en) 2012-01-31 2013-08-01 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
ITMI20120608A1 (it) * 2012-04-13 2013-10-14 Dipharma Francis Srl Procedimento per la preparazione di un inibitore delle proteasi virali in forma amorfa
WO2013178031A1 (en) * 2012-06-01 2013-12-05 Sunshine Lake Pharma Co., Ltd. New forms of telaprevir and preparation methods thereof
WO2014096343A1 (en) * 2012-12-21 2014-06-26 Sandoz Ag Novel forms of telaprevir
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
CA2903831A1 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim International Gmbh Solid oral dosage formulation of hcv inhibitor in the amorphous state
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN110193013B (zh) * 2019-07-02 2022-02-08 力品药业(厦门)股份有限公司 一种去乙酰真菌环氧乙酯固体分散体及其制备方法
CA3256935A1 (en) * 2022-05-16 2023-11-23 Day One Biopharmaceuticals, Inc. PAN-RAF KINASE INHIBITOR ORAL LIQUID SUSPENSION
EP4582092A1 (en) * 2022-10-12 2025-07-09 Chugai Seiyaku Kabushiki Kaisha Composition containing peptide, surfactant, and polymer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
JPH107558A (ja) * 1996-06-19 1998-01-13 Eisai Co Ltd 溶解性改善製剤
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
ES2306646T3 (es) * 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US6627760B1 (en) * 2001-06-25 2003-09-30 Astrazeneca Ab Amorphous compound
MXPA04004657A (es) * 2001-11-14 2004-08-13 Teva Pharma Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
US6642204B2 (en) * 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
CA2543696A1 (en) * 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
TWI437990B (zh) * 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途

Similar Documents

Publication Publication Date Title
JP2008501802A5 (https=)
RU2006147247A (ru) Фармацевтические композиции
JP2009530415A5 (https=)
JP2009530415A (ja) 医薬組成物
TWI666020B (zh) 固體分散製劑
JP2018503595A (ja) ペプチド模倣大環状分子およびその製剤
CN103118681A (zh) 固体组合物
AU2013358897A1 (en) Pharmaceutical compositions
WO2011063076A1 (en) Methods of treating hepatitis c virus with oxoacetamide compounds
RU2342926C2 (ru) Способ получения низкокристаллического олтипраза или аморфного олтипраза
CN103228278A (zh) 治疗hcv感染的组合疗法
CN101068829B (zh) 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
CN110958880A (zh) 固体分散制剂
WO2006132342A1 (ja) ロフルミラスト点眼液
KR20170083108A (ko) C형 간염에 대한 장기 작용 약학적 조성물
US20170314022A1 (en) Combination long acting compositions and methods for hepatitis c
CN104780921A (zh) Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合
JPWO2001087303A1 (ja) 水性液剤
DE602004010291T2 (de) Hcv-hemmende sulfonamide
JP2016538312A (ja) 非晶質のコビシスタットの固体分散体
CN108727450A (zh) 肝递送抗丙肝前体药物核苷环磷酸酯化合物及应用
JPS60166613A (ja) 肝疾患治療剤
KR20140003203A (ko) 설폰아미드계 화합물을 유효성분으로 포함하는 ｃ형 간염의 예방 또는 치료용 약학적 조성물